Stereotactic body radiation therapy for lung metastases

Umberto Ricardi, Andrea Riccardo Filippi, Alessia Guarneri, Riccardo Ragona, Cristina Mantovani, Francesca Giglioli, Angela Botticella, Patrizia Ciammella, Cristina Iftode, Lucio Buffoni, Enrico Ruffini, Giorgio Vittorio Scagliotti

Research output: Contribution to journalArticle

94 Citations (Scopus)

Abstract

Introduction: Stereotactic body radiation therapy (SBRT) has an emerging role in patients affected with pulmonary metastases. Purpose of this study was to evaluate efficacy and tolerability of SBRT in a cohort of patients treated between 2003 and 2009 at our institution. Methods: A total of 61 patients with oligometastatic lung tumors (single pulmonary nodules in 73.7%) were included in the study. SBRT was performed with a stereotactic body frame and a 3D-conformal technique. Fifty-one patients received 26. Gy in 1 fraction, 22 a dose of 45. Gy in 3 fractions and 3 a dose of 36. Gy in 4 fractions. Primary tumor was lung cancer in 45.7% of patients, colorectal cancer in 21.3% and a variety of other origins in 33%. The primary endpoint was local control, secondary endpoints were survival and toxicity. Results: After a median follow-up interval of 20.4 months, local control rates at 2 and 3 years were 89% and 83.5%, overall survival 66.5% and 52.5%, cancer-specific survival 75.4% and 67%, progression-free survival 32.4% and 22.3%. Tumor volume was significantly associated to survival, with highest rates in patients with single small tumors. Median survival time was 42.8 months, while median progression-free survival time was 11.9 months. Toxicity profiles were good, with just one case of grade III toxicity (pneumonitis). Conclusion: This study shows that SBRT is an effective and safe local treatment option for patients with lung metastases. Definitive results are strictly correlated to clinical selection of patients.

Original languageEnglish
Pages (from-to)77-81
Number of pages5
JournalLung Cancer
Volume75
Issue number1
DOIs
Publication statusPublished - Jan 2012

Fingerprint

Radiotherapy
Neoplasm Metastasis
Lung
Survival
Disease-Free Survival
Neoplasms
Tumor Burden
Patient Selection
Colorectal Neoplasms
Lung Neoplasms
Pneumonia

Keywords

  • Local treatment
  • Lung metastases
  • Oligometastases
  • Radiosurgery
  • Single-dose radiotherapy
  • Stereotactic radiotherapy

ASJC Scopus subject areas

  • Oncology
  • Pulmonary and Respiratory Medicine
  • Cancer Research

Cite this

Ricardi, U., Filippi, A. R., Guarneri, A., Ragona, R., Mantovani, C., Giglioli, F., ... Scagliotti, G. V. (2012). Stereotactic body radiation therapy for lung metastases. Lung Cancer, 75(1), 77-81. https://doi.org/10.1016/j.lungcan.2011.04.021

Stereotactic body radiation therapy for lung metastases. / Ricardi, Umberto; Filippi, Andrea Riccardo; Guarneri, Alessia; Ragona, Riccardo; Mantovani, Cristina; Giglioli, Francesca; Botticella, Angela; Ciammella, Patrizia; Iftode, Cristina; Buffoni, Lucio; Ruffini, Enrico; Scagliotti, Giorgio Vittorio.

In: Lung Cancer, Vol. 75, No. 1, 01.2012, p. 77-81.

Research output: Contribution to journalArticle

Ricardi, U, Filippi, AR, Guarneri, A, Ragona, R, Mantovani, C, Giglioli, F, Botticella, A, Ciammella, P, Iftode, C, Buffoni, L, Ruffini, E & Scagliotti, GV 2012, 'Stereotactic body radiation therapy for lung metastases', Lung Cancer, vol. 75, no. 1, pp. 77-81. https://doi.org/10.1016/j.lungcan.2011.04.021
Ricardi U, Filippi AR, Guarneri A, Ragona R, Mantovani C, Giglioli F et al. Stereotactic body radiation therapy for lung metastases. Lung Cancer. 2012 Jan;75(1):77-81. https://doi.org/10.1016/j.lungcan.2011.04.021
Ricardi, Umberto ; Filippi, Andrea Riccardo ; Guarneri, Alessia ; Ragona, Riccardo ; Mantovani, Cristina ; Giglioli, Francesca ; Botticella, Angela ; Ciammella, Patrizia ; Iftode, Cristina ; Buffoni, Lucio ; Ruffini, Enrico ; Scagliotti, Giorgio Vittorio. / Stereotactic body radiation therapy for lung metastases. In: Lung Cancer. 2012 ; Vol. 75, No. 1. pp. 77-81.
@article{e43548a387ec4aeca0006400e0d825fc,
title = "Stereotactic body radiation therapy for lung metastases",
abstract = "Introduction: Stereotactic body radiation therapy (SBRT) has an emerging role in patients affected with pulmonary metastases. Purpose of this study was to evaluate efficacy and tolerability of SBRT in a cohort of patients treated between 2003 and 2009 at our institution. Methods: A total of 61 patients with oligometastatic lung tumors (single pulmonary nodules in 73.7{\%}) were included in the study. SBRT was performed with a stereotactic body frame and a 3D-conformal technique. Fifty-one patients received 26. Gy in 1 fraction, 22 a dose of 45. Gy in 3 fractions and 3 a dose of 36. Gy in 4 fractions. Primary tumor was lung cancer in 45.7{\%} of patients, colorectal cancer in 21.3{\%} and a variety of other origins in 33{\%}. The primary endpoint was local control, secondary endpoints were survival and toxicity. Results: After a median follow-up interval of 20.4 months, local control rates at 2 and 3 years were 89{\%} and 83.5{\%}, overall survival 66.5{\%} and 52.5{\%}, cancer-specific survival 75.4{\%} and 67{\%}, progression-free survival 32.4{\%} and 22.3{\%}. Tumor volume was significantly associated to survival, with highest rates in patients with single small tumors. Median survival time was 42.8 months, while median progression-free survival time was 11.9 months. Toxicity profiles were good, with just one case of grade III toxicity (pneumonitis). Conclusion: This study shows that SBRT is an effective and safe local treatment option for patients with lung metastases. Definitive results are strictly correlated to clinical selection of patients.",
keywords = "Local treatment, Lung metastases, Oligometastases, Radiosurgery, Single-dose radiotherapy, Stereotactic radiotherapy",
author = "Umberto Ricardi and Filippi, {Andrea Riccardo} and Alessia Guarneri and Riccardo Ragona and Cristina Mantovani and Francesca Giglioli and Angela Botticella and Patrizia Ciammella and Cristina Iftode and Lucio Buffoni and Enrico Ruffini and Scagliotti, {Giorgio Vittorio}",
year = "2012",
month = "1",
doi = "10.1016/j.lungcan.2011.04.021",
language = "English",
volume = "75",
pages = "77--81",
journal = "Lung Cancer",
issn = "0169-5002",
publisher = "Elsevier Ireland Ltd",
number = "1",

}

TY - JOUR

T1 - Stereotactic body radiation therapy for lung metastases

AU - Ricardi, Umberto

AU - Filippi, Andrea Riccardo

AU - Guarneri, Alessia

AU - Ragona, Riccardo

AU - Mantovani, Cristina

AU - Giglioli, Francesca

AU - Botticella, Angela

AU - Ciammella, Patrizia

AU - Iftode, Cristina

AU - Buffoni, Lucio

AU - Ruffini, Enrico

AU - Scagliotti, Giorgio Vittorio

PY - 2012/1

Y1 - 2012/1

N2 - Introduction: Stereotactic body radiation therapy (SBRT) has an emerging role in patients affected with pulmonary metastases. Purpose of this study was to evaluate efficacy and tolerability of SBRT in a cohort of patients treated between 2003 and 2009 at our institution. Methods: A total of 61 patients with oligometastatic lung tumors (single pulmonary nodules in 73.7%) were included in the study. SBRT was performed with a stereotactic body frame and a 3D-conformal technique. Fifty-one patients received 26. Gy in 1 fraction, 22 a dose of 45. Gy in 3 fractions and 3 a dose of 36. Gy in 4 fractions. Primary tumor was lung cancer in 45.7% of patients, colorectal cancer in 21.3% and a variety of other origins in 33%. The primary endpoint was local control, secondary endpoints were survival and toxicity. Results: After a median follow-up interval of 20.4 months, local control rates at 2 and 3 years were 89% and 83.5%, overall survival 66.5% and 52.5%, cancer-specific survival 75.4% and 67%, progression-free survival 32.4% and 22.3%. Tumor volume was significantly associated to survival, with highest rates in patients with single small tumors. Median survival time was 42.8 months, while median progression-free survival time was 11.9 months. Toxicity profiles were good, with just one case of grade III toxicity (pneumonitis). Conclusion: This study shows that SBRT is an effective and safe local treatment option for patients with lung metastases. Definitive results are strictly correlated to clinical selection of patients.

AB - Introduction: Stereotactic body radiation therapy (SBRT) has an emerging role in patients affected with pulmonary metastases. Purpose of this study was to evaluate efficacy and tolerability of SBRT in a cohort of patients treated between 2003 and 2009 at our institution. Methods: A total of 61 patients with oligometastatic lung tumors (single pulmonary nodules in 73.7%) were included in the study. SBRT was performed with a stereotactic body frame and a 3D-conformal technique. Fifty-one patients received 26. Gy in 1 fraction, 22 a dose of 45. Gy in 3 fractions and 3 a dose of 36. Gy in 4 fractions. Primary tumor was lung cancer in 45.7% of patients, colorectal cancer in 21.3% and a variety of other origins in 33%. The primary endpoint was local control, secondary endpoints were survival and toxicity. Results: After a median follow-up interval of 20.4 months, local control rates at 2 and 3 years were 89% and 83.5%, overall survival 66.5% and 52.5%, cancer-specific survival 75.4% and 67%, progression-free survival 32.4% and 22.3%. Tumor volume was significantly associated to survival, with highest rates in patients with single small tumors. Median survival time was 42.8 months, while median progression-free survival time was 11.9 months. Toxicity profiles were good, with just one case of grade III toxicity (pneumonitis). Conclusion: This study shows that SBRT is an effective and safe local treatment option for patients with lung metastases. Definitive results are strictly correlated to clinical selection of patients.

KW - Local treatment

KW - Lung metastases

KW - Oligometastases

KW - Radiosurgery

KW - Single-dose radiotherapy

KW - Stereotactic radiotherapy

UR - http://www.scopus.com/inward/record.url?scp=83555173457&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=83555173457&partnerID=8YFLogxK

U2 - 10.1016/j.lungcan.2011.04.021

DO - 10.1016/j.lungcan.2011.04.021

M3 - Article

C2 - 21726918

AN - SCOPUS:83555173457

VL - 75

SP - 77

EP - 81

JO - Lung Cancer

JF - Lung Cancer

SN - 0169-5002

IS - 1

ER -